Sirt1 Is a Regulator of Bone Mass and a Repressor of Sost Encoding for Sclerostin, a Bone Formation Inhibitor

被引:188
作者
Cohen-Kfir, Einav [1 ]
Artsi, Hanna [1 ]
Levin, Avi [1 ]
Abramowitz, Eva [1 ]
Bajayo, Alon [2 ]
Gurt, Irina [1 ]
Zhong, Lei [3 ]
D'Urso, Agustina [3 ]
Toiber, Debra [3 ]
Mostoslavsky, Raul [3 ]
Dresner-Pollak, Rivka [1 ]
机构
[1] Hadassah Hebrew Univ Med Ctr, Endocrinol & Metab Serv, Dept Med, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel
[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA
基金
以色列科学基金会;
关键词
DECREASES ADIPOCYTE FORMATION; MESENCHYMAL STEM-CELLS; VAN-BUCHEM-DISEASE; PARATHYROID-HORMONE; OSTEOBLAST DIFFERENTIATION; CALORIE RESTRICTION; BMP ANTAGONIST; PPAR-GAMMA; LIFE-SPAN; GENE;
D O I
10.1210/en.2011-1128
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Sirt1, the mammalian ortholog of the yeast Sir2 (silent information regulator 2), was shown to play an important role in metabolism and in age-associated diseases, but its role in skeletal homeostasis and osteoporosis has yet not been studied. Using 129/Sv mice with a germline mutation in the Sirt1 gene, we demonstrate that Sirt1 haplo-insufficient (Sirt1(+/-)) female mice exhibit a significant reduction in bone mass characterized by decreased bone formation and increased marrow adipogenesis. Importantly, we identify Sost, encoding for sclerostin, a critical inhibitor of bone formation, as a novel target of Sirt1. Using chromatin immunoprecipitation analysis, we reveal that Sirt1 directly and negatively regulates Sost gene expression by deacetylating histone 3 at lysine 9 at the Sost promoter. Sost down-regulation by small interfering RNA and the administration of a sclerostin-neutralizing antibody restore gene expression of osteocalcin and bone sialoprotein as well as mineralized nodule formation in Sirt1(+/-) marrow-derived mesenchymal stem cells induced to osteogenesis. These findings reveal a novel role for Sirt1 in bone as a regulator of bone mass and a repressor of sclerostin, and have potential implications suggesting that Sirt1 is a target for promoting bone formation as an anabolic approach for treatment of osteoporosis. (Endocrinology 152: 4514-4524, 2011)
引用
收藏
页码:4514 / 4524
页数:11
相关论文
共 46 条
[1]
PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors [J].
Akune, T ;
Ohba, S ;
Kamekura, S ;
Yamaguchi, M ;
Chung, UI ;
Kubota, N ;
Terauchi, Y ;
Harada, Y ;
Azuma, Y ;
Nakamura, K ;
Kadowaki, T ;
Kawaguchi, H .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (06) :846-855
[2]
Activation of Sirt1 Decreases Adipocyte Formation during Osteoblast Differentiation of Mesenchymal Stem Cells [J].
Backesjo, Carl-Magnus ;
Li, Yan ;
Lindgren, Urban ;
Haldosen, Lars-Arne .
CELLS TISSUES ORGANS, 2009, 189 (1-4) :93-97
[3]
Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells [J].
Bäckesjö, CM ;
Li, Y ;
Lindgren, U ;
Haldosén, LA .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (07) :993-1002
[4]
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease [J].
Balemans, W ;
Patel, N ;
Ebeling, M ;
Van Hul, E ;
Wuyts, W ;
Lacza, C ;
Dioszegi, M ;
Dikkers, FG ;
Hildering, P ;
Willems, PJ ;
Verheij, JBGM ;
Lindpaintner, K ;
Vickery, B ;
Foernzler, D ;
Van Hul, W .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (02) :91-97
[5]
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) [J].
Balemans, W ;
Ebeling, M ;
Patel, N ;
Van Hul, E ;
Olson, P ;
Dioszegi, M ;
Lacza, C ;
Wuyts, W ;
Van den Ende, J ;
Willems, P ;
Paes-Alves, AF ;
Hill, S ;
Bueno, M ;
Ramos, FJ ;
Tacconi, P ;
Dikkers, FG ;
Stratakis, C ;
Lindpaintner, K ;
Vickery, B ;
Foernzler, D ;
Van Hul, W .
HUMAN MOLECULAR GENETICS, 2001, 10 (05) :537-543
[6]
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis [J].
Bellido, T ;
Ali, AA ;
Gubrij, I ;
Plotkin, LI ;
Fu, Q ;
O'Brien, CA ;
Manolagas, SC ;
Jilka, RL .
ENDOCRINOLOGY, 2005, 146 (11) :4577-4583
[7]
SIRT1 transgenic mice show phenotypes resembling calorie restriction [J].
Bordone, Laura ;
Cohen, Dena ;
Robinson, Ashley ;
Motta, Maria Carla ;
van Veen, Ed ;
Czopik, Agnieszka ;
Steele, Andrew D. ;
Crowe, Hayley ;
Marmor, Stephen ;
Luo, Jianyuan ;
Gu, Wei ;
Guarente, Leonard .
AGING CELL, 2007, 6 (06) :759-767
[8]
Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β [J].
Bowers, JL ;
Tyulmenkov, VV ;
Jernigan, SC ;
Klinge, CM .
ENDOCRINOLOGY, 2000, 141 (10) :3657-3667
[9]
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein [J].
Brunkow, ME ;
Gardner, JC ;
Van Ness, J ;
Paeper, BW ;
Kovacevich, BR ;
Proll, S ;
Skonier, JE ;
Zhao, L ;
Sabo, PJ ;
Fu, YH ;
Alisch, RS ;
Gillett, L ;
Colbert, T ;
Tacconi, P ;
Galas, D ;
Hamersma, H ;
Beighton, P ;
Mulligan, JT .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (03) :577-589
[10]
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice [J].
Cheng, HL ;
Mostoslavsky, R ;
Saito, S ;
Manis, JP ;
Gu, YS ;
Patel, P ;
Bronson, R ;
Appella, E ;
Alt, FW ;
Chua, KF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (19) :10794-10799